Lutetium Lu 177 Vipivotide Tetraxetan

What is Lutetium Lu 177 Vipivotide Tetraxetan?

Lutetium Lu 177 vipivotide tetraxetan — sold as Pluvicto by Novartis — is a radioligand therapy for metastatic prostate cancer. It is built from three pieces bolted together: a glutamate-urea-lysine pharmacophore that binds prostate-specific membrane antigen (PSMA), a linker, and the macrocyclic chelator DOTA (whose international nonproprietary name is tetraxetan) holding a single atom of lutetium-177. The lutetium-177 emits beta particles that travel roughly a millimetre or two through tissue, so once the molecule docks onto a PSMA-displaying cell the radiation deposits its energy in that cell and its immediate neighbours. It is worth being precise about what kind of molecule this is, because the atlas is a peptide directory and Pluvicto sits at the edge of the category. Unlike DOTATATE — a genuine eight-amino-acid somatostatin analogue — the PSMA-617 targeting vector is a peptidomimetic rather than a ribosomal peptide. Its Glu-urea-Lys core descends structurally from N-acetyl-aspartyl-glutamate (NAAG), the neuropeptide that PSMA (which is also the enzyme glutamate carboxypeptidase II) naturally cleaves. The urea nitrogen coordinates the zinc in the enzyme's active site while the glutamate and lysine carboxylates occupy the S1' pocket. Some chemistry sources call it a urea-containing peptide and some call it a small-molecule ligand; peptidomimetic is the honest description. The practical significance is that Pluvicto is half of a theranostic pair. Before treatment, the same PSMA target is imaged with a gallium-68 or fluorine-18 PSMA PET agent; only patients whose tumours light up are treated. That companion-diagnostic requirement is written into the label, not left to clinical judgment.

What Lutetium Lu 177 Vipivotide Tetraxetan Is Investigated For

Pluvicto's strongest evidence is exactly where it was first approved: PSMA-positive metastatic castration-resistant prostate cancer already treated with an androgen receptor pathway inhibitor (ARPI) and one or two taxane regimens. In the phase 3 VISION trial that setting produced both a radiographic progression-free survival benefit (8.7 vs 3.4 months) and an overall survival benefit (15.3 vs 11.3 months) versus protocol-permitted standard care. Those are the numbers the approval rests on, and they are the numbers to quote. Everything earlier in the disease course is a weaker claim, and the label is broader than the survival evidence. PSMAfore moved the drug ahead of chemotherapy and clearly delayed radiographic progression (median 11.6 vs 5.6 months on updated analysis), but its final overall survival analysis was not statistically significant on an intention-to-treat basis (24.5 vs 23.1 months, HR 0.91, P = 0.20) — most plausibly because 60% of the control arm crossed over to receive the drug anyway. PSMAddition then met its rPFS primary endpoint in hormone-sensitive disease (HR 0.72) at a second interim analysis with overall survival still immature. So the fair summary across the whole spectrum is: Pluvicto reliably delays radiographic progression wherever it has been tested, and has demonstrated a survival benefit in one setting — the post-taxane one. TheraP is the useful counterweight. Randomised against cabazitaxel after docetaxel, Pluvicto produced better PSA responses and a gentler side-effect profile, but overall survival was indistinguishable (restricted mean survival 19.1 vs 19.6 months, p = 0.77). That makes it a genuine alternative to cabazitaxel rather than a clear upgrade — a tolerability choice more than a survival one.

History & Discovery

PSMA-617 came out of the German Cancer Research Center (DKFZ) and Heidelberg University Hospital in the mid-2010s, from a group including Klaus Kopka, Uwe Haberkorn, Clemens Kratochwil and Frederik Giesel. The scientific problem they were solving was not finding a PSMA binder — Glu-urea-Lys pharmacophores modelled on NAAG had been described years earlier — but engineering the region between that binder and the chelator. Earlier PSMA radioligands delivered too much dose to kidneys and salivary glands relative to tumour. PSMA-617's distinguishing feature is a linker tuned to improve tumour retention and the tumour-to-kidney ratio, which is what made a therapeutic rather than merely diagnostic application viable. The clinical path was unusual. Rather than a conventional phase 1-2-3 progression, 177Lu-PSMA-617 spread first through German compassionate-use and named-patient programmes, generating a large retrospective dataset before any randomised trial existed. Heidelberg also published the first human experience with the alpha-emitting actinium-225 version in 2016, which produced striking imaging responses in patients refractory to the beta-emitter and opened the alpha-therapy line that continues today. Endocyte licensed the compound and was acquired by Novartis in 2018; the VISION trial enrolled from June 2018 to October 2019 and read out in 2021, and Australia's investigator-initiated TheraP trial ran in parallel with a tougher comparator. FDA approval followed on 23 March 2022 under NDA 215833 — the first PSMA-targeted radioligand therapy approved anywhere, and approved the same day as its companion diagnostic LOCAMETZ. The European Commission authorised it on 9 December 2022. Demand immediately outstripped supply: Novartis's manufacturing constraints produced treatment delays through 2022 and 2023 and became a subject of editorial comment in the nuclear medicine literature, with new production facilities and competing PSMA radioligands held up as the eventual remedy. The label then widened twice — to taxane-naive castration-resistant disease in March 2025 on the strength of PSMAfore, and to androgen-pathway-modulation-naive or -sensitive disease in 2026 on the strength of PSMAddition, with the revised label effective 12 August 2026.

How It Works

Most prostate cancer cells carry a protein called PSMA on their surface, and they carry far more of it than healthy tissue does. Pluvicto is a small molecule that grabs onto PSMA, with a radioactive lutetium atom bolted to the other end. Once it docks, the cell pulls it inside and the lutetium delivers a short burst of beta radiation that damages the DNA of that cell and the cells immediately around it. Because the radiation only travels a millimetre or two, most of the damage lands on tumour rather than on healthy organs.

PSMA — prostate-specific membrane antigen, also known as glutamate carboxypeptidase II or folate hydrolase 1 — is a type II transmembrane glycoprotein that is modestly expressed in normal prostate, kidney tubules, salivary glands and small intestine, and massively overexpressed in prostate adenocarcinoma, typically by a factor of 100 to 1,000. Expression tends to rise further with dedifferentiation and with castration resistance, which is why a PSMA-directed agent becomes more rather than less attractive as the disease advances. The PSMA-617 vector exploits the enzyme's natural substrate chemistry. Its glutamate-urea-lysine motif is a peptidomimetic modelled on N-acetyl-aspartyl-glutamate: the urea carbonyl coordinates the catalytic zinc ion while the flanking carboxylate groups occupy the S1' recognition pocket, giving nanomolar affinity. A linker region — optimised during development specifically to improve tumour retention and reduce kidney dose relative to earlier PSMA ligands — connects that binding motif to the DOTA chelator. DOTA cages lutetium-177 with enough kinetic stability that free lutetium is not released into circulation in meaningful amounts. After binding, the PSMA-ligand complex is internalised by clathrin-mediated endocytosis and trafficked to endosomes, where the radiometal is effectively trapped inside the cell. Lutetium-177 decays with a 6.6-day physical half-life, emitting beta-minus particles with a maximum energy around 0.5 MeV and a mean soft-tissue range of roughly 0.7 mm (maximum about 2 mm). That range is the therapeutic sweet spot for micrometastatic and small-volume disease: long enough to produce a crossfire effect that also kills adjacent PSMA-negative tumour cells, short enough to spare most normal tissue. Lutetium-177 also emits low-abundance gamma photons at 113 and 208 keV, which is what makes post-treatment SPECT/CT imaging and patient-specific dosimetry possible from the therapy dose itself. The dose-limiting organs follow directly from where PSMA sits in normal tissue. Salivary and lacrimal glands explain xerostomia and dry eye; renal proximal tubules explain the kidney dosimetry focus; bone marrow explains the cytopenias. The VISION dosimetry substudy quantified absorbed doses to these organs and reported that renal and multiorgan safety held up over the treatment course, with an update published in 2026.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Lutetium Lu 177 Vipivotide Tetraxetan:

• 01Overall survival before the post-taxane setting. VISION demonstrated a survival benefit; PSMAfore did not reach statistical significance on intention-to-treat (HR 0.91, P=0.20) with 60% crossover, and PSMAddition's survival data are immature. Whether moving the drug earlier extends life or only delays radiographic progression is the central unresolved question about this agent.
• 02Optimal sequencing against cabazitaxel, radium-223, PARP inhibitors and the emerging actinium-225 PSMA agents. TheraP showed equivalence to cabazitaxel on survival, so sequence rather than substitution is the live question, and no randomised trial has tested the orderings that matter.
• 03Re-treatment after an initial six cycles. The label does not address it, trials did not study it, and observational series are small — yet patients who respond well and later progress are an obvious re-treatment population.
• 04Long-term secondary malignancy risk, particularly myelodysplastic syndrome and acute leukaemia. Follow-up in the pivotal trials was too short, in populations too sick, to characterise late haematologic effects. This gap grows more important with every expansion into earlier disease, where patients survive long enough for late effects to appear.
• 05Patient-specific dosimetry versus fixed dosing. The label prescribes a fixed 7.4 GBq per cycle, but post-treatment SPECT/CT makes individualised dose calculation feasible, and dosimetry studies show wide inter-patient variation in tumour and organ absorbed dose. Whether dosimetry-guided dosing improves outcomes has not been tested in a randomised trial.
• 06Salivary gland protection. Xerostomia is the defining toxicity, mechanistically attributable to PSMA expression in salivary tissue, yet no protective strategy has convincing evidence behind it — external cooling, sialagogues and local vasoconstriction have all been tried with unimpressive or conflicting results.
• 07Which PSMA PET threshold should govern eligibility. VISION, TheraP and PSMAddition used different imaging criteria and different tracers, and quantitative PET analyses show that uptake intensity predicts benefit continuously rather than dichotomously — so 'PSMA-positive' is a cruder gate than the underlying biology warrants.
• 08Management of PSMA-negative or FDG-discordant disease, which is both common and associated with markedly worse outcomes. TheraP's excluded cohort had a restricted mean survival of 11.0 months with no radioligand option, and no strategy addresses this group specifically.

Forms & Administration

Supplied as a single-dose vial of clear, colourless to slightly yellow solution for intravenous infusion, at 1,000 MBq/mL (27 mCi/mL) at calibration. Administered only in nuclear medicine or radiation oncology facilities licensed for therapeutic radiopharmaceuticals, by personnel trained in handling them, using waterproof gloves and effective shielding. Given as an intravenous infusion over several minutes — commonly by gravity, syringe pump or peristaltic pump with a saline flush — followed by hydration and instructions to void frequently. Patient selection requires a PSMA PET scan with LOCAMETZ (gallium Ga 68 gozetotide) or another approved PSMA PET product. There is no oral, subcutaneous or compounded form, and none is chemically plausible: the molecule is a short-half-life radiopharmaceutical produced in a licensed radiopharmacy and delivered on a decay-corrected schedule.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Pluvicto is a prescription therapeutic radiopharmaceutical administered only in licensed nuclear medicine facilities. Nothing on this page is a dosing recommendation, and there is no legitimate route by which a patient obtains or self-administers it.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Lutetium Lu 177 Vipivotide Tetraxetan Is NOT For

Drug & Supplement Interactions

There are no classical pharmacokinetic drug interactions of the cytochrome P450 variety for Pluvicto. The molecule is a radiolabelled peptidomimetic cleared largely renally and unchanged, it is given at microgram mass doses, and no formal interaction studies of consequence underpin the label. The interactions that matter are additive-toxicity and sequencing questions instead. The most practical concern is cumulative myelosuppression. Overlapping Pluvicto with other marrow-toxic treatments — taxane chemotherapy, radium-223, external beam radiotherapy to large marrow-bearing fields, or PARP inhibitors such as olaparib — raises the risk of prolonged cytopenias, and the available evidence does not resolve what the ideal order should be. A published series of patients treated shortly after failing radium-223 found the combination tolerable, but the question of whether earlier bone-seeking radiopharmaceutical exposure compromises later radioligand therapy is still unsettled, and treatment sequencing in the ARPI-pre-exposed population is the subject of ongoing review rather than settled guidance. Androgen receptor pathway inhibitors interact with Pluvicto in a more interesting way: they appear to modulate the target itself. ARPIs can upregulate PSMA expression, which is part of the mechanistic rationale for the ENZA-p combination trial and for the PSMAddition design giving the radioligand alongside ADT and an ARPI rather than after them. That is a pharmacodynamic interaction working in the patient's favour, not a hazard. Somatostatin analogues do not interfere here, unlike with DOTATATE-based therapy where they compete for the same receptor — a useful contrast, since the two lutetium-177 products are frequently confused. Nephrotoxic agents warrant ordinary caution given renal clearance and renal PSMA expression, and the amino-acid renal-protection infusion used with Lutathera is not part of the Pluvicto protocol.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions